insights_auto
Por qué ha subido BVNKF 7,13%?
Profundizarchevron_right
BVNKF:OTCMKTS
Bavarian Nordic A/S
36,06 US$
arrow_upward
+7,13%(+2,40) 1 d
8 oct, 16:00:00 GMT-4 · USD
search
Todos los símbolos
| Símbolo | Precio | Cambio | % de cambio |
|---|
insights_autoGenerando estadísticas principales de BVNKF...
Abrir
33,99 US$
Alto
36,06 US$
Bajo
33,99 US$
Cap. burs.
2815,57 M
Vol. medio
7,00
Volumen
208,00
Máximo en 52 sem.
37,22 US$
Mínimo en 52 sem.
27,69 US$
Beta
1,46
Acciones en circulación
79,26 M
N.º de empleados
2 mil
Abrir
33,99 US$
Alto
36,06 US$
Bajo
33,99 US$
Cap. burs.
2815,57 M
Vol. medio
7,00
Volumen
208,00
Máximo en 52 sem.
37,22 US$
Mínimo en 52 sem.
27,69 US$
Beta
1,46
Acciones en circulación
79,26 M
N.º de empleados
2 mil
Noticias
De fuentes web y partners de noticias
The Copenhagen Post
·
hace 1 día
Bavarian Nordic raises 2026 revenue forecast on stronger travel vaccine sales
TradingView
·
hace 2 días
Bavarian Nordic Raises Revenue, EBITDA Margin Forecasts
GlobeNewswire
·
hace 2 días
Bavarian Nordic Upgrades Full-Year 2026 Financial Guidance After Strong Travel Health Performance
Perfil
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination.
In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
Acerca de Bavarian Nordic A/S